AF
CRSP icon

Advisornet Financial’s CRISPR Therapeutics CRSP Stock Holding History

Advisornet Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$381K Buy
8,003
+1,111
+16% +$58.6K 0.02% 446
2025
Q4 		$361K Buy
6,892
+58
+0.8% +$3.47K 0.02% 463
2025
Q3 		$443K Buy
6,834
+701
+11% +$40.2K 0.03% 406
2025
Q2 		$298K Buy
6,133
+1,060
+21% +$41K 0.02% 481
2025
Q1 		$173K Buy
5,073
+2,595
+105% +$110K 0.01% 584
2024
Q4 		$97.5K Buy
2,478
+1,181
+91% +$55.8K 0.01% 696
2024
Q3 		$60.9K Buy
1,297
+197
+18% +$10K ﹤0.01% 846
2024
Q2 		$59.4K Sell
1,100
-60
-5% -$3.47K 0.01% 765
2024
Q1 		$79.1K Buy
1,160
+135
+13% +$9.66K 0.01% 694
2023
Q4 		$64.2K Hold
1,025
– – 0.01% 747
2023
Q3 		$46.5K Sell
1,025
-250
-20% -$12.9K ﹤0.01% 803
2023
Q2 		$71.6K Buy
1,275
+750
+143% +$42.6K 0.01% 724
2023
Q1 		$23.7K Hold
525
– – ﹤0.01% 1019
2022
Q4 		$21.3K Sell
525
-2
-0.4% -$106 ﹤0.01% 1036
2022
Q3 		$34K Hold
527
– – ﹤0.01% 961
2022
Q2 		$32K Sell
527
-33
-6% -$1.94K ﹤0.01% 996
2022
Q1 		$35K Buy
560
+25
+5% +$1.57K ﹤0.01% 1077
2021
Q4 		$41K Sell
535
-490
-48% -$42.8K ﹤0.01% 1074
2021
Q3 		$115K Buy
1,025
+13
+1% +$1.63K 0.01% 740
2021
Q2 		$164K Hold
1,012
– – 0.01% 646
2021
Q1 		$123K Buy
1,012
+960
+1,846% +$145K 0.01% 689
2020
Q4 		$8K Buy
52
+50
+2,500% +$5.91K ﹤0.01% 1334
2020
Q3 		$0 Hold
2
– – ﹤0.01% 1744
2020
Q2 		$0 Buy
+2
New +$117 ﹤0.01% 1793

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Advisornet Financial's CRSP Position: Q1 2026 in Review

Advisornet Financial increased its CRISPR Therapeutics (CRSP) stake by 16% in Q1 2026, buying an estimated $58.6K and bringing the position to 8,003 shares worth $381K. The position accounts for 0.02% of the portfolio, ranked #446.

Advisornet Financial first reported a position in CRSP in Q2 2020 and has held it in 24 quarters since. The position peaked at $443K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Advisornet Financial held 8,003 shares of CRISPR Therapeutics worth $381K as of Q1 2026.
  • Advisornet Financial bought 1,111 CRISPR Therapeutics shares in Q1 2026, an estimated $58.6K.
  • CRISPR Therapeutics made up 0.02% of Advisornet Financial's portfolio in Q1 2026, its #446 holding.
  • Advisornet Financial first reported a position in CRISPR Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Advisornet Financial's CRISPR Therapeutics position peaked at $443K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Advisornet Financial's 13F filing for Q1 2026, filed 17 Apr 2026.